Showing 7741-7750 of 9940 results for "".
- FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for ADhttps://practicaldermatology.com/news/fda-gives-green-light-innocares-clinical-trial-tyk2-inhibitor-icp-332-ad/2467004/InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332. ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatmen
- Parental E-Cigarette Use Linked to Pediatric ADhttps://practicaldermatology.com/news/parental-e-cigarette-use-linked-pediatric-ad/2467003/Electronic cigarette use by parents is associated with increased chances of pediatric atopic dermatitis, according to an article published last month by JAMA Dermatology. In a retrospective cross-sectional analysis of the 2014 to 2018 National Health Interview Survey, researchers found tha
- FDA-Cleared Fractional Laser for Hair Loss Now Availablehttps://practicaldermatology.com/news/fda-cleared-fractional-laser-hair-loss-now-available/2467000/The only US Food and Drug Administration-cleared fractional laser for safe, effective, and natural hair loss treatment is now available on the US market with the launch of FoLix from Lumenis Be. Ltd. Utilizing fractional laser and proprietary technology tailored for hair, FoLix offers res
- Tirbanibulin Approved for Actinic Keratosishttps://practicaldermatology.com/news/tirbanibulin-approved-actinic-keratosis/2466999/The U.S. Food and Drug Administration (FDA) has approved tirbanibulin (Klisyri, Almirall) for the treatment of actinic keratosis on an expanded area of the scalp and face, according to a news release from the manufacturer. The tirbanibulin ointment, 1% is a microtubule inhibitor with a f
- Roflumilast Cream 0.3% Improves Patient-Reported Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/patient-reported-outcomes-improve-roflumilast-cream-03-psoriasis/2466998/A recent study suggested efficacy for roflumilast cream 0.3% for the topical treatment of plaque psoriasis. Researchers for the study pooled data from two Phase 3 clinical trials (DERMIS-1 and DERMIS-2), which included patients aged ≥2 years with plaque psoriasis affecting between 2% and
- Lebrikizumab Maintains Efficacy Through 52 Weekshttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-through-52-weeks/2466977/New data from a pooled analysis of the ADvocate1 and ADvocate2 trials indicates lebrikizumab was efficacious for treating atopic dermatitis (AD) over a year-long period. “Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient reported ou
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- Report: Advancements and Demand To Drive Aesthetic Medicine Market to $212.5 Billion by 2032https://practicaldermatology.com/news/advancements-and-demand-drive-aesthetic-medicine-market-2125-billion-2032/2463206/A new report forecasts growth in the aesthetic medicine market. Currently valued at US$ 75.6 billion, the report says that the value of the market is projected to reach US$ 212.5 billion by 2032, reflecting a robust compound annual growth rate of 12.17% from 2024 to 2032. The report attri
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://practicaldermatology.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i